Hypothesis

Baseline circulating indole‑3‑propionic acid (IPA) predicts slower epigenetic aging and lower mortality risk, but only when hepatic pregnane X receptor (PXR) activity is sufficient to maintain intestinal barrier integrity and limit systemic endotoxin exposure.

Rationale

IPA activates PXR and AhR, regulating inflammatory and oxidative stress pathways in gut fibroblasts, macrophages, and endothelium [5,6,7,8]. In mouse models, IPA‑driven PXR signaling reduces intestinal fibrosis and vascular dysfunction [6,8], yet human data remain correlative and underpowered [1,2,3]. Importantly, IPA is one of the few tryptophan metabolites that crosses the blood‑brain barrier, lowering microglial TNF‑α while boosting neuronal BDNF and NGF [9,3] . However, the bioavailability of IPA to the brain depends on gut barrier function; luminal endotoxins can induce hepatic inflammation that attenuates PXR signaling and divert IPA metabolism. This creates a conditional relationship: high IPA only translates into neuroprotective and anti‑aging effects when the gut‑liver axis is intact.

Predictions

1. In a longitudinal cohort (n > 2000) baseline plasma IPA will be inversely associated with GrimAge acceleration (standardized β ≈ ‑0.15) after adjusting for age, sex, BMI, and CRP.
2. The IPA‑GrimAge association will be significantly stronger (interaction p < 0.01) in participants with high hepatic PXR target gene expression (e.g., CYP3A4, CYP2B6) measured in peripheral blood mononuclear cells.
3. Participants with low IPA but high endotoxin activity (LBP or sCD14) will show the fastest epigenetic aging, indicating that IPA’s benefit is contingent on low systemic microbial translocation.
4. Supplementation with a sustained‑release IPA formulation will increase circulating IPA ≥ 2‑fold and, only in the high‑PXR subgroup, reduce GrimAge acceleration by 0.5 years over 12 months, without affecting CRP.

Experimental Design

• Cohort: Use existing metabolomic data from the TwinsUK and BLSA (> 30 000 subjects) [11] to quantify baseline IPA and compute DNA‑migration clocks (PhenoAge, GrimAge).
• PXR Activity: Measure hepatic PXR activation via circulating CYP3A4 activity (midazolam clearance surrogate) or blood‑based CYP3A4 mRNA.
• Endotoxin Load: Quantify plasma LPS‑binding protein (LBP) and soluble CD14 (sCD14).
• Analysis: Fit linear mixed models with IPA, PXR activity, and their interaction as fixed effects; include random intercepts for family/twin pairs. Test three‑way interaction with endotoxin load to evaluate conditionality.
• Intervention Arm: Random‑placebo controlled trial of delayed‑release IPA (1 g/day) vs placebo for 12 months in 200 participants stratified by high vs low PXR activity; primary outcome change in GrimAge.

Potential Outcomes

• Confirmation: Significant IPA × PXR interaction would support the gut‑brain rheostat model, elevating IPA from a correlative marker to a mechanistically conditioned biomarker of aging.
• Refutation: Absence of interaction or a uniform IPA effect irrespective of PXR/endotoxin levels would suggest that IPA acts independently of barrier integrity, redirecting focus toward direct neuronal or systemic pathways. Either outcome refines the mechanistic framework and informs whether IPA supplementation should be targeted to individuals with preserved hepatic PXR signaling.